BioDelivery Sciences International (NSDQ:BDSI) said today that its clonidine topical gel for pain relief in patients with diabetic neuropathy failed in a phase IIb clinical trial. Raleigh, N.C.-based BioDelivery will halt any further development of the painkiller.

In the phase IIb clinical trial, BioDelivery’s topical gel did not demonstrate a statistically significant difference in pain relief compared to a placebo. The company licensed the clonidine topical gel from Arcion Therapeutics to develop and commercialize it in March 2013.

Get the full story at our sister site, Drug Delivery Business News.